In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to EACVI Silver Members, Fellows of the ESC and Young combined Members

Left ventricular mechanics reveals a benign reduction in ejection fraction after valve replacement in aortic stenosis

Session Poster session 2

Speaker Kush Patel

Event : EuroCMR 2019

  • Topic : imaging
  • Sub-topic : Cardiac Magnetic Resonance: Valve Disease
  • Session type : Poster Session

Authors : K Patel (London,GB), RE Bachiller (Madrid,ES), R Boubertakh (London,GB), S Moir (Melbourne,AU), R Kozor (Sydney,AU), R Davies (London,GB), A Bhuva (London,GB), P Scully (London,GB), AS Herrey (London,GB), C Manisty (London,GB), JC Moon (London,GB), TA Treibel (London,GB)

K Patel1 , RE Bachiller2 , R Boubertakh1 , S Moir3 , R Kozor4 , R Davies1 , A Bhuva1 , P Scully1 , AS Herrey1 , C Manisty1 , JC Moon1 , TA Treibel1 , 1Barts Health NHS Trust, Cardiac Imaging - London - United Kingdom of Great Britain & Northern Ireland , 2University Hospital La Paz - Madrid - Spain , 3Monash University - Melbourne - Australia , 4University of Sydney - Sydney - Australia ,

European Heart Journal - Cardiovascular Imaging ( 2019 ) 20 ( Supplement 2 ), ii346

Aortic stenosis (AS) results in left ventricular (LV) hypertrophy, which regresses after aortic valve replacement (AVR), both accompanied by changes in LV ejection fraction (LVEF).  Strain imaging by CMR feature tracking (CMR-FT) may provide a more sensitive assessment of these alterations. 

To assess LV strain prior to and after AVR in patients with supranormal (EF=75%) and normal/impaired LVEF (EF<75%). 

CMR-FT analysis was performed on standard cine images of patients with severe AS, before and 1-year after surgical AVR.

48 patients had EF=75% (age 70±11; 44% male) and 53 had EF<75% (age 69±9; 66% male). At baseline, patients with EF<75% had higher LV mass index (LVMi) and worse LV strain (Table 1) than EF=75%. In EF<75%, strain parameters were strongly correlated with LVEF (R>0.7; p<0.001), however, in EF=75% this relationship was lost (Fig 1). 

1-year post AVR, patients with EF=75% had lower LVMi regression and a reduction in LVEF compared to EF<75%. Whereas LV strain parameters and NT-proBNP levels improved in patients with EF<75%, they remained unchanged in EF=75% (Table 1).

Supra-normal LVEF in AS patients reduces post-operatively with LV strain and NT-proBNP confirming that this is a benign normalisation.

Baseline LVEF<75% (n=53) LVEF≥75% (n=48) P value
LVMi 99.3±27.7 78.1±19.5 <0.001
LVEF 60.6±14.7 82.5±4.1 <0.001
CS -14.8±5.3 -22.0±3.8 <0.001
RS 27.5±13.1 47.7±13.8 <0.001
LS -14.8±5.3 -19.8±4.0 <0.001
NT-proBNP 145 (49 to 425) 30 (18 to 51) <0.001
1 year
Change in LVMi -22.2±18.6 -13.8±5.3 0.007
Change in LVEF 9.1±15.2 -3.1±5.3 <0.001
Change in CS -4.0±5.8 0.0±4.4 <0.001
Change in RS 11.8±16.7 4.4±19.2 0.044
Change in LS -3.6±5.8 -1.9±6.2 0.173
Change in NT-proBNP -50 (-378 to -12) 0 (-11 to 23) <0.001
Remodelling and functional parameters in EF<75% and EF=75%. LVMi- left ventricular mass index, LVEF- left ventricular ejection fraction, CS- circumferential strain, RS- radial strain, LS- longitudinal strain, NT-proBNP- N-terminal pro-brain natriuretic peptide.

The free consultation period for this content is over.

It is now only available year-round to EACVI Silver Members, Fellows of the ESC and Young combined Members

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are